Main navigation

• Home
• About us
• Medicines
• Research
• Careers
• Responsibility
• Partnering
• Media
• Investors
  • Corporate governance
  • Shareholder information
  • Investor tools
  • Directors' shareholdings
  • SEC filings
  • Financial calendar
  • Financial results
  • Annual reports
  • Presentations & webcasts
  • Financial highlights
  • Strategy
  • FAQs
  • Investor contacts

You are here

• Home

• Investor relations

• Latest news collapse

  • 29 October 2009 AstraZeneca PLC Third Quarter & Nine Months Results 2009

    Strong business performance has been driven by good operating execution bolstered by revenue upsides from Toprol-XL and H1N1 vaccine sales. Core EPS target for the year has been increased and progress has been made on the pipeline with the approval of ONGLYZA(TM), the European submission for Brilinta and new external collaborations, tempered by the disappointing news on Zactima.

  more news

  • previous
  • • 1
    • 2
    • 3
    • 4
    • 5
  • next

  Research & Development collapse

  We focus our research on six disease areas where we believe our skills and experience can make the most difference.

  • Read about our disease area focus
  • Read about our pipeline progress
  • Review our pipeline summary

  Share price tools collapse

  • Interactive stock charts
  • Share holding calculator
  • Share price look-up
  • Share price history

• Annual Report 2008 collapse

  • Online annual report
  • Order a printed copy

  Latest presentation collapse

  November 2009

  • Investor Relations general presentation (PDF 3 Mb)

  • Other presentations

  Financial results collapse

  Third Quarter & Nine Months results 2009 announced Thursday, 29 October 2009.

  • View details of the event
  • View financial calendar

  Managing your shares collapse

  • Dividend information
  • Shareholder forms
  • Share registration contacts
  • Annual General Meeting
  • FAQs

  Currency Guidance 2009 collapse

  • View 2009 currency guidance

Not signed in

Page tools

• Print
• Bookmark this page

Share price